Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BRVE
BRAVEHEART BIO, INC.
NASDAQ
$27.58
▲ UP 0.58% (0.16)

KEY STATISTICS

Market Cap$1.95 B
52w High$32.00
52w Low$24.61
Dividend Yield—
Frequency—
P/E—
Volume130.49K
Shares Out.70.65M

COMPANY

LEADERSHIP

Travis Murdoch
CHIEF EXECUTIVE
Travis Murdoch

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 6, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
30

PRICE

$27.58 ▲ UP 0.58% (+$0.16)
$27.25$27.50$27.75$28.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM27.58

About Braveheart Bio, Inc.

http://www.braveheart.bio ↗

Braveheart Bio, Inc., founded in May 2024 and based in San Francisco, CA, develops therapeutics for hypertrophic cardiomyopathy, with its lead candidate BHB-1839 being a small-molecule cardiac myosin inhibitor.

INDUSTRY

Biotechnology

A PRODUCT BRAVEHEART BIO, INC. IS KNOWN FOR

BHB-1893
BHB-1893

BHB-1893 is a late-stage, oral small-molecule cardiac myosin inhibitor by Braveheart Bio, in development for treating both obstructive and non-obstructive hypertrophic cardiomyopathy.

COMPETITORS

COMPETITOR
BMY COMPARE
CYTK COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
FMED
0.27% · 5.2K

INSIDER TRADES

★
DIRECTOR
Agarwala Vineeta
— · —
2026-08-07
★
DIRECTOR, 10 PERCENT OWNER:
ORBIMED ADVISORS LLC
Purchase · 9.1M shares
2026-08-07
★
10 PERCENT OWNER
AH Bio Fund IV, L.P.
Purchase · 9.1M shares
2026-08-07
★
DIRECTOR, 10 PERCENT OWNER:
Chimovits Erez
Purchase · 273.3K shares
2026-08-07